

RETENTION IN HIV PROGRAMMES

Defining the challenges and identifying solutions

MEETING REPORT
13–15 SEPTEMBER 2011, GENEVA

RETENTION IN HIV PROGRAMMES

Defining the challenges and identifying solutions

MEETING REPORT
13–15 SEPTEMBER 2011, GENEVA

WHO Library Cataloguing-in-Publication Data

Retention in HIV programmes: defining the challenges and identifying solutions: meeting report, 13-15 September 2011.

1.HIV infections – drug therapy. 2.Medication adherence. 3.Follow-up studies. 4.Patient dropouts. 5.HIV infections – prevention and control. 6.HIV infections – diagnosis. 7.Anti-retroviral agents – therapeutic use. I.World Health Organization.

ISBN 978 92 4 150368 6

(NLM classification: WC 503.2)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Switzerland.

TABLE OF CONTENTS

1. Introduction	3
2. Defining the problem	6
3. Country experiences with retention: Risk factors for LTFU	11
4. Retention issues in special groups	16
4.1 PMTCT	16
4.2 Paediatrics and adolescents	16
4.3 Patients with HIV/TB co-infection	18
5. Monitoring and evaluation	20
6. Working groups – M&E	25
6.1. Terms	25
6.2 Period definitions	26
6.3 Missing data	27
7. Responding to low retention	30
7.1 Country experiences with strategies to improve retention	30
7.2 Decentralization and integration	35
7.3 WHO guidance for adapting HIV service delivery: to improve patient and population health outcomes	36
8. Retention strategies (working groups)	38
8.1 Retention in special populations	38
9. Summary and conclusions	44
9.1 Steps towards better patient retention across the continuum of care	44
9.2 Decentralization and integration of HIV services	45
9.3 Engagement of community and patients	46
9.4 Health workforce related issues	47
9.5 Monitoring and evaluation	47
9.6 Conclusions	47
10. Next steps	49

Meeting agenda	52
List of participants	57
Abbreviations	59
Glossary of terms	60
References	62

1. INTRODUCTION

WHO convened a global consultative meeting on retention in HIV care from September 13-15, 2011, in Geneva, Switzerland.

Despite significant success in scaling up ART programmes worldwide, many people living with HIV (PLHIV) start ART late in the progression of HIV infection, resulting in high rates of early mortality on ART (1). Currently, the majority of PLHIV remain undiagnosed and many do not access HIV care and treatment despite a positive test. PLHIV are lost at every step along the continuum of care, particularly in the period between HIV diagnosis and initiation of ART. It is now recognized that poor retention of patients in care – especially in the pre-ART period (*Steps 2-3 on the continuum of care; please see Glossary of Terms, p40*) – is a major driver of this poor programme performance and increased morbidity and mortality.

'Retention in HIV care' can be defined as continuous engagement from diagnosis in a package of prevention, treatment, support and care services. 'Retention in care' can be defined from the moment of initial engagement in care, when a person with HIV is linked successfully to services, to assessment for eligibility, initiation on ART and retention in lifelong ART care. However, in other studies and reports it sometimes includes the period from diagnosis to successful linkage to care. This first stage is most problematic to describe and document as people can be tested in a large number of different settings both in the community and in clinical facilities. Linking people to ongoing care from clinical settings may be easier to facilitate and document than from community settings which may not have effective links to services or efficient ways of tracking and documenting linkages. In the meeting, four **stages of retention in the continuum of care** starting from a positive HIV test to enrolment in care, enrolment in care to ART eligibility, ART eligibility to initiation of ART, and finally continuation of lifelong ART, were described and discussed. Retention is critical to reduce HIV-related morbidity and mortality, reduce the incidence of new infections in children and adults, and reduce development of ART resistance.

Preparatory work for the meeting identified a significant challenge with inconsistencies in, confusion about and lack of consensus on how key steps were defined along the continuum of care and the conceptual distinction between 'loss to follow-up' and 'disengagement from care'. A most useful definition of 'loss to follow-up' should refer to patients with *unknown outcomes*. 'Loss to follow-up' should point to gaps in knowledge and information systems. 'Disengagement from care' reflects patient issues for those who cease to access care – and demands a service delivery response. Although these concepts are overlapping, they cannot be considered synonymous without hindering discussion. In other words, knowing the outcomes of the lost (which will differ along the continuum of care and across settings by transfers, deaths, early deaths, leaving care altogether and by reason), is requisite for a data-driven response to loss to follow-up and disengagement from care.

Historically, strategies to address retention have focused on the ART period.¹ Retention on ART is better documented and currently this is the area given the greatest attention and for which systems and resources are prioritized. For patients who have received an HIV diagnosis, the obstacles to enrolment in care, retention in care until eligible for ART and initiation of ART are greater, and this area – retention of patients in care prior to ART initiation – was also an important focus of this meeting. Retaining patients in care in the pre-ART period is especially important as early initiation of ART reduces HIV-related mortality, can support women in the reproductive age group providing an opportunity to expand PMTCT coverage and partner involvement, and may have an impact on HIV transmission, both sexual and vertical. Furthermore there is an opportunity to provide other clinical services in the 'pre-ART' period such as interventions to reduce morbidity and mortality (e.g. co-trimoxazole (CTX) prophylaxis and, isoniazid preventive therapy (IPT)) and HIV prevention interventions.

As background for this meeting, a review of published literature was carried out and loss to follow-up (LTFU) at each stage noted (2). Despite the fact that there may be considerable bias in data from published literature as this often reflects data collected from well-resourced and well functioning programmes, it is worth noting that the highest rates of LTFU occur between testing and enrolment, (3) and up to 80% of patients diagnosed with HIV infection may be LTFU between testing and initiation of ART (4).

The key objectives of this meeting were:

- 1.To highlight the challenges around retention of patients between HIV diagnosis and enrollment and ongoing participation in HIV care with a focus on country-specific issues.
- 2.To highlight the importance of diligent monitoring and evaluation to improve HIV care programmes.
- 3.To identify gaps in documenting and monitoring LTFU.
- 4.To propose standardized definitions for key terms such as loss-to follow-up, and retention, including standardized period definitions.
- 5.To share country experiences and propose strategies to enhance retention in care with a focus on improving service delivery as part of Treatment 2.0.

The outcomes of the meeting are expected to serve as a foundation for future WHO normative guidance and to strengthen future programme support for retention in care.

The meeting brought together a wide range of experts working in the field of retention (see full participant list and agenda pp 36–42).

¹ Indicators to monitor retention on ART, as defined by UNGASS, include the percentage of adults and children with HIV known to be alive and on treatment 12 months after the initiation of ART.

This meeting report summarizes the presentations given by key researchers in the field and the presentations from a number of countries and specific programmes (all presentations and background papers are available on the retention meeting EZcollab website). Summaries of the discussions from the working groups are also presented in this report.

Prior to the meeting a country survey (5) was also carried out. This qualitative survey, administered online or by telephone, aimed to gauge views and experiences on retention along the continuum of care. Responses were provided by a wide range of HIV care programmes with input from WHO country staff, Ministry of Health officials and clinicians. At least 2 representatives from each of the 22 priority HIV countries provided input. Meeting participants were also invited to share unpublished data from their country programmes. (Full details from the survey and additional programme information is also available on the website).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28508

